Why is ALINT.PA stock falling intraday?

ALINT.PA stock is down intraday largely due to thin liquidity and higher-than-normal volume. Today’s volume of 166,168 shares versus average 14,631 magnifies selling. Weak fundamentals, negative EPS, and limited news flow also weigh on the price.

What is Meyka AI’s forecast for ALINT.PA stock?

Meyka AI's forecast model projects a monthly level of **€0.09**, implying **-52.63%** from the current **€0.19**. This is a model-based projection and not a guarantee.

What are the main financial risks for IntegraGen SA (ALINT.PA)?

Major risks include negative EPS **-0.04**, a price-to-book near **3.37**, and debt-to-equity **1.23**. Low market cap increases liquidity risk and amplifies price swings on poor trading days.

Where can I find official listings or benchmark comparisons for ALINT.PA?

Use Euronext listings and benchmark pages for context. See broader Euronext lists and peer comparisons here: Euronext list [source](https://stockanalysis.com/list/euronext-paris/?page=2) and regional peer compare [source](https://de.investing.com/pro/ENXTPA:ALPAT/compare/ENXTPA:ALINT,ENXTPA:VLA,ENX?

EU Stocks

ALINT.PA IntegraGen SA slides on EURONEXT 11 Feb 2026: assess liquidity risk

ByHuzaifa Zahoor February 11, 2026February 11, 2026

ALINT.PA stock is trading at €0.19 intraday on EURONEXT after hitting a day low of €0.15 with volume of 166,168 shares. The intraday move places IntegraGen SA (ALINT.PA) among top losers on 11 Feb 2026 in Europe. Traders cite thin market depth, a 50-day average near €0.15, and weak fundamentals as pressure points for the Healthcare biotechnology name.